-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Examining the Malignant Genome in CAR-T Patients

Symposia: Scientific Workshop on Understanding and Overcoming Tumor-intrinsic Resistance to CAR-T Therapies for Lymphoid Malignancies Program: Scientific Workshops
Friday, December 6, 2024: 3:42 PM-4:18 PM
Room 28 A-D (San Diego Convention Center)
Moderator:
and Jonathan H. Schatz, MD, University of Miami
Disclosures:
Schatz: Affimed NV: Consultancy; WCG: Consultancy; Acrotech Biopharma Inc.: Membership on an entity's Board of Directors or advisory committees.

The malignant genome is comparatively understudied for markers of resistance to CD19-directed CAR-T cells for the treatment of large B-cell lymphomas. Here we review two approaches that have revealed genomic resistance markers on samples from CAR-T treated lymphoma patients. Discussion will compare and contrast sample requirements and discovery power of these and other approaches and the importance of further characterizing findings in functional models.
Moderator Introduction

Jonathan H. Schatz, MD

University of Miami, Miami, FL
The Unique Power of Whole Genome Sequencing

Francesco Maura, MD

University of Miami, Coral Gables, NY
Circulating Tumor DNA: All You Need Is Blood

Ash A. Alizadeh, MD, PhD

Stanford University, San Mateo, CA
Panel Discussion
See more of: Scientific Workshop on Understanding and Overcoming Tumor-intrinsic Resistance to CAR-T Therapies for Lymphoid Malignancies
See more of: Scientific Workshops
<< Previous Session | Next Session >>